Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:SLNO 30 December 2025 - 2 February 2026

Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next

Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next

Soleno Therapeutics shares jumped 8.9% to $42.00 Monday, outpacing a broad biotech rally. The move follows attention on VYKAT XR’s U.S. launch, with preliminary 2025 revenue reported at up to $191 million and 1,250 patient starts. Investors are awaiting full financial results in late February and monitoring upcoming investor conference appearances. No new company news was released Monday.
2 February 2026
·
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Soleno Therapeutics shares fell 5.6% to $42.95 Friday, underperforming the biotech sector after law firms announced “investigations” tied to past short-seller claims about Vykat XR. The company reported $66 million in quarterly revenue from the drug, approved for Prader-Willi syndrome, with 1,043 patient start forms since March. The stock hovered just above its 52-week low. Next update expected late February.
9 January 2026
··

Stock Market Today

  • Smiths Group Shares Fall 6% Despite Strategic Sales and Capital Returns
    March 20, 2026, 7:37 AM EDT. Shares of Smiths Group (LSE:SMIN) dropped 5.9% to 2,222p following mixed half-year results and slightly lowered full-year guidance. The company saw organic revenue growth of 4% and a 7.2% rise in headline operating profit to £248 million, with margins improving 50 basis points to 17.2%. However, statutory profits fell sharply due to one-off charges, causing a 17.4% drop in earnings per share. CEO Roland Carter highlighted the sale of Smiths Detection and Smiths Interconnect as transformational, alongside a £1.5 billion planned shareholder return through 2027. Analysts noted investor disappointment over modest revenue growth and trimmed guidance, despite a 5.4% dividend increase. Long-term outlook remains positive with disposals, acquisitions, and capital returns aiming for mid-term 5-7% organic growth and 21-23% margins, seen as a potential buying opportunity by some market watchers.
Go toTop